Cathepsin B‐Cleavable Doxorubicin Prodrug Nanoparticles for Eliciting Cancer‐Specific Immunogenic Cell Death and Minimizing Systemic Toxicity
Advanced Healthcare Materials · 2026
DOI: 10.1002/adhm.202504414 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, 2026. Verfasst von Nayeon Shim und 11 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy, Graduate School of Pharmaceutical Sciences, Ewha Womans University, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Cathepsin B, Prodrugs, Doxorubicin, Nanoparticles. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 47 Literaturangaben. Gefördert von: Ministry of Health and Welfare, Ministry of Science and ICT, South Korea.
Abstract (Originalsprache)
Doxorubicin (DOX) is a potent anticancer drug, but its poor tumor selectivity and systemic toxicity limit clinical use and hinder cancer immunotherapy despite its ability to induce immunogenic cell death (ICD). To overcome these limitations, we developed self‐assembling, cathepsin B‐cleavable peptide ( Phe‐Arg‐Arg‐X : FRRX)‐DOX prodrugs forming nanoparticles via hydrophobic and π – π interactions. Among them, the FRRL‐DOX nanoparticles (cathepsin B‐cleavable DOX prodrug nanoparticles; CatB‐NPs) exhibited stable nanoparticle structure with an average diameter of 165.1 ± 24.7 nm and enhanced tumor accumulation through the enhanced permeation and retention (EPR) effect. In the cell culture systems, CatB‐NPs showed the cancer cell‐specific ICD while minimizing non‐specific damage to normal cells and immune cells. In the CT26 tumour‐bearing mice, CatB‐NPs exhibited improved pharmacokinetics, enhanced tumor accumulation, and significantly greater therapeutic efficacy. When combined with anti‐PD‐L1 antibody, CatB‐NPs achieved 100% complete tumor regression, with elevated dendritic cell (DC) activation, cytotoxic T cell infiltration, and durable immunological memory. Furthermore, CatB‐NPs greatly reduced the cardiotoxicity and splenic toxicity associated with free DOX, preserving tissue structure and immune function. This study highlights the clinical potential of self‐assembling and cathepsin B‐cleavable prodrug nanoparticles as a next‐generation anticancer drug with improved safety and immune compatibility.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Pharmacy, Graduate School of Pharmaceutical Sciences, Ewha Womans University, Seoul, Republic of Korea.
- Graduate Program in Innovative Biomaterials Convergence, Ewha Womans University, Seoul, Republic of Korea.
- Department of Chemical and Biomolecular Engineering, Sogang University, Seoul, Republic of Korea.
- Department of Chemical and Biomolecular Engineering, Yonsei University, Seoul, Republic of Korea.
ORCID-Profile: Kwangmeyung Kim
Förderung
- Ministry of Health and Welfare
- Ministry of Science and ICT, South Korea
Zitieren
APA
Shim, N., Kim, J., Song, S., Yoo, H., Kim, Y., Oh, Y., Hwang, N., Goo, J., Hong, S., Yu, J., Cho, H., & Kim, K. (2026). Cathepsin B‐Cleavable Doxorubicin Prodrug Nanoparticles for Eliciting Cancer‐Specific Immunogenic Cell Death and Minimizing Systemic Toxicity. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.202504414
Vancouver
Shim N, Kim J, Song S, Yoo H, Kim Y, Oh Y, et al. Cathepsin B‐Cleavable Doxorubicin Prodrug Nanoparticles for Eliciting Cancer‐Specific Immunogenic Cell Death and Minimizing Systemic Toxicity. Advanced Healthcare Materials. 2026. doi:10.1002/adhm.202504414
BibTeX
@article{Shim2026,
author = {Shim, Nayeon and Kim, Jinseong and Song, Sukyung and Yoo, Hyeonji and Kim, Yeonjin and Oh, Yoojeong and Hwang, Namcheol and Goo, Jagyeong and Hong, Seeun and Yu, Jinha and Cho, Hanhee and Kim, Kwangmeyung},
title = {Cathepsin B‐Cleavable Doxorubicin Prodrug Nanoparticles for Eliciting Cancer‐Specific Immunogenic Cell Death and Minimizing Systemic Toxicity},
journal = {Advanced Healthcare Materials},
year = {2026},
doi = {10.1002/adhm.202504414}
}
EUVIMED